Early Detection of Breast Cancer

Breast Neoplasms Clinical Trial

Official title:

An Evaluation of a Circulating Tumor Cell-based Test (TriNetra™-Breast) for Breast Cancer Screening in Women Aged 40 and Above

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06043661
• Other study ID #: HUM00217725
• Status: Recruiting
• Start date: February 9, 2023
• Est. completion date: December 2025

Study information

• Verified date: September 2023
• Source: Datar Cancer Genetics Inc
• Contact: Ulka Vaishampayan, MBBS,MD
• Phone: +17349367813
• Email: vaishamu[@]umich.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer. The TriNetra™Breast test should be a useful breast cancer screening option for asymptomatic women 40 years of age and older. This pivotal study is designed to provide evidence of test performance and to demonstrate its safety in the intended use population in the USA.

Description:

This prospective, case-cohort study evaluates the sensitivity and specificity of the TriNetra™-Breast test for breast cancer (adenocarcinoma) screening in women aged 40 years and older. Approximately 700 subjects will be enrolled in one of the two non-overlapping cohorts in this study. Cohort A will enroll about 500 subjects with a standard risk of breast cancer who fulfill the enrollment criteria. Cohort B will enroll approximately 200 subjects with a mammogram result of BI-RADS 4 or 5. The results of TriNetra™ -Breast will be compared with the results of mammography. The corresponding diagnostic biopsy pathology results obtained as the standard of care will be correlated with test results to confirm the performance estimates (when indicated). Mammography will be the reference standard of evaluation of breast screening status for cohort A. Histopathology report will be the reference standard to evaluate the malignant or non-malignant clinical status for cohort B. Availability of histopathological results is mandatory for the evaluation of cohort B.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 700
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

A). For Cohort A (500 subjects are targeted to enroll)

1. No prior diagnosis of (any) cancer

2. Women aged 40 years and above at the time of mammography

3. Provision of signed informed consent

4. Capable of providing adequate health history

5. No co-morbidity which could impair study participation or sample collection

6. Blood draw within sixty (60) days of performance of screening mammography

7. A redacted/deidentified mammography report will be available and provided

8. If any prior mammography was performed, the BI-RADS score should be 1 or 2 or 3

9. Willingness to accept follow-up contact every 6 months for up to 2 years.

10. Agreeable to share any future biopsy or imaging data for a maximum of 2 years from study blood draw. B). For Cohort B (BI-RADS 4 and 5) (200 subjects are targeted to enroll)

1. No prior diagnosis of (any) cancer

2. Women aged 40 years and above at the time of mammography

3. Provision of signed informed consent

4. Current mammography indicating BI-RADS 4a,4b, 4c, or 5

5. Capable of providing adequate health history

6. No co-morbidity which could impair study participation or sample collection

7. Blood draw within sixty (60) days of mammography and prior to biopsy of the breast

8. Yet to undergo tissue diagnostic procedure for breast lesion such as fine needle, core, or excisional biopsy

9. A redacted/deidentified mammography report and redacted/de-identified pathology report will be available and provided

10. Willingness to accept follow-up contact every 6 months for up to 2 years.

11. Agreeable to share any future repeat biopsy or imaging data for a maximum of 2 years from study blood draw. C). Exclusion Criteria

1. Prior diagnosis of (any) cancer

2. Subjects who are receiving any investigational agent.

3. Pregnant women are excluded from this study

4. Breastfeeding women are excluded from this study

5. Blood transfusion within 30 days prior to screening,

6. Subject has any condition that in the opinion of the investigator should preclude participation in the study.

Related Conditions & MeSH terms

• Breast Neoplasms

Locations

Country	Name	City	State
United States	Rogel Cancer Center	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Datar Cancer Genetics Inc

Country where clinical trial is conducted

United States, 

References & Publications (1)

Crook T, Leonard R, Mokbel K, Thompson A, Michell M, Page R, Vaid A, Mehrotra R, Ranade A, Limaye S, Patil D, Akolkar D, Datta V, Fulmali P, Apurwa S, Schuster S, Srinivasan A, Datar R. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers (Basel). 2022 Jul 9;14(14):3341. doi: 10.3390/cancers14143341. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint of this study is the sensitivity and specificity of TriNetra Breast for breast cancer screening in women 40 years and older, using mammography and histopathology confirmed diagnosis (when relevant) as the reference methods.	The study evaluates the clinical sensitivity and specificity of the TriNetra Breast in Mammography-Negative (BIRAD 1/2/3) and Mammography-Positive (BIRAD 4/5) Cohorts	2 years
Secondary	The Positive Predictive Values (PPV) and Negative Predictive Values (NPV)	The study evaluates the PPV and NPV of the TriNetra Breast for breast cancer screening in women 40 years and older, using mammography and histopathology confirmed diagnosis (when relevant) as the reference methods.	2 years
Secondary	Detection rates by TNM stage	The study evaluates the detection rates (sensitivity in %) by TNM stage for the TriNetra Breast test, using surgical pathology evaluation as a reference.	2 years
Secondary	Clinical performance in dense breast findings on mammography	The study evaluates the clinical sensitivity and specificity (in %) for the TriNetra Breast test in dense breast findings on mammography	2 years
Secondary	Sensitivity and specificity for ductal carcinoma in situ (DCIS) detection	The study evaluates the clinical sensitivity and specificity (in %) for the TriNetra Breast test in ductal carcinoma in situ (DCIS) detection.	2 years